A Milestone Phase I Randomized, Double-Blind Clinical Trial

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

LOS ANGELES--(BUSINESS WIRE)--Nov 30, 2023--

Related Keywords

California , United States , Haukeland , Hordaland , Norway , Charalampos Tzoulis , Kendall Knysch , Nasdaq , Chromadex External Research Program , Translational Research In Parkinson , Chromadex Corporation , Movement Disorders Society , Nature Communications , Chromadex Corp , Haukeland University Hospital , Kg Jebsen Center , Sysmed Research Center , University Of Bergen , Nicotinamide Adenine Dinucleotide , Cell Metabolism , Rob Fried , Translational Research , Neuro Sysmed Research Center , Looking Statements , Securities Act , Exchange Act , Annual Report , Quarterly Reports , Chromadex Media Contact , Public Relations , Relations Contact , Business Wire , Region ,